Specialist healthcare group, Ark Therapeutics, and serious diseases therapies developer PsiOxus Therapeutics, said their partnership has successfully achieved its first milestone.
The firms have manufactured PsiOxus's colorectal cancer product, and as a result PsiOxus has initiated final pre-clinical toxicology studies of the product.
Martyn Williams, Chief Executive Officer of Ark said: "We are delighted that our early success with ColoAd1 will enable the development of this exciting product to move forward as planned and we look forward to continuing to provide full support to our partner as their programme moves into the clinic."
MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
The share price rose 4.69% to 3.35p by 15:17.
__
NR
-
What is the 25x retirement rule and does it work?The 25x retirement rule has been around for decades but many experts question if it is a suitable strategy
-
When is the self-assessment tax return deadline?If you are self-employed, rent out a property or earn income from savings or investments, you may need to complete a self-assessment tax return. We run through the deadlines you need to know about
